We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

157 hedge funds and large institutions have $646M invested in Collegium Pharmaceutical in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 68 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

219% more call options, than puts

Call options by funds: $628K | Put options by funds: $197K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.85% less ownership

Funds ownership: 108.09%107.24% (-0.85%)

9% less funds holding

Funds holding: 172157 (-15)

12% less capital invested

Capital invested by funds: $734M → $646M (-$88.4M)

24% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 68

32% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 25

Holders
157
Holders Change
-15
Holders Change %
-8.72%
% of All Funds
2.64%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
17
Increased
52
Reduced
68
Closed
25
Calls
$628K
Puts
$197K
Net Calls
+$431K
Net Calls Change
+$209K
Name Holding Trade Value Shares
Change
Change in
Stake
MOACM
126
Mutual of America Capital Management
New York
$101K +$12.2K +725 +15%
Wells Fargo
127
Wells Fargo
California
$84K -$1.14M -67,644 -93%
Zurich Cantonal Bank
128
Zurich Cantonal Bank
Switzerland
$81K
KBC Group
129
KBC Group
Belgium
$59K -$258K -15,366 -82%
DA
130
Denali Advisors
California
$53K +$21.9K +1,300 +76%
AIP
131
Ameritas Investment Partners
Nebraska
$49K
Fidelity Investments
132
Fidelity Investments
Massachusetts
$42K +$2.1K +125 +6%
Nisa Investment Advisors
133
Nisa Investment Advisors
Missouri
$42K +$32.8K +1,950 +443%
MLICM
134
Metropolitan Life Insurance Company (MetLife)
New York
$39.5K
Allspring Global Investments
135
Allspring Global Investments
North Carolina
$31K -$1.08M -64,158 -97%
GWM
136
Geneos Wealth Management
Colorado
$30K -$8.41K -500 -23%
AssetMark Inc
137
AssetMark Inc
California
$20K +$10.9K +646 +142%
CAPTRUST Financial Advisors
138
CAPTRUST Financial Advisors
North Carolina
$16K -$20.7K -1,230 -57%
UBS Group
139
UBS Group
Switzerland
$16K -$16K -950 -52%
Osaic Holdings
140
Osaic Holdings
Arizona
$14K
PNC Financial Services Group
141
PNC Financial Services Group
Pennsylvania
$9K -$29.6K -1,758 -79%
TC
142
Truvestments Capital
Florida
$6K +$5.77K +343 New
Macquarie Group
143
Macquarie Group
Australia
$5K
Bessemer Group
144
Bessemer Group
New Jersey
$4K -$4.53K -269 -54%
TCWM
145
Total Clarity Wealth Management
Illinois
$4K +$3.37K +200 New
CA
146
Crewe Advisors
Utah
$3K +$3.31K +197 New
MCC
147
Money Concepts Capital
Florida
$2K -$1.68K -100 -50%
LC
148
Lindbrook Capital
California
$2K -$1.29K -77 -43%
Daiwa Securities Group
149
Daiwa Securities Group
Japan
$2K +$858 +51 +67%
S
150
SignatureFD
Georgia
$2K +$1.68K +100 +270%

COLL Hedge Fund Activity: Q2 2022 in Review

157 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2022, worth a combined $646M — down 12% from $734M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of COLL and 17 opened new positions — a net loss of 8 holders — while 68 trimmed existing stakes and 52 added.

The largest buyer was Principal Financial Group, adding an estimated $5.4M. The largest seller was Pacer Advisors, exiting entirely with an estimated $4.5M sold.

  • 157 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2022, down from 172 in Q1 2022.
  • Funds reported $646M of Collegium Pharmaceutical stock for Q2 2022, down 12% quarter-over-quarter.
  • 17 funds opened new Collegium Pharmaceutical positions in Q2 2022 and 25 closed out, a net change of -8 holders.
  • The largest Collegium Pharmaceutical buyer in Q2 2022 was Principal Financial Group, an estimated $5.4M added.
  • The largest Collegium Pharmaceutical seller in Q2 2022 was Pacer Advisors, an estimated $4.5M sold.

Based on aggregated 13F filings for Q2 2022.